JP2013510155A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510155A5
JP2013510155A5 JP2012537925A JP2012537925A JP2013510155A5 JP 2013510155 A5 JP2013510155 A5 JP 2013510155A5 JP 2012537925 A JP2012537925 A JP 2012537925A JP 2012537925 A JP2012537925 A JP 2012537925A JP 2013510155 A5 JP2013510155 A5 JP 2013510155A5
Authority
JP
Japan
Prior art keywords
amino
alkyl
quinazolinyl
methyloxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012537925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510155A (ja
JP5836963B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/054927 external-priority patent/WO2011056740A1/en
Publication of JP2013510155A publication Critical patent/JP2013510155A/ja
Publication of JP2013510155A5 publication Critical patent/JP2013510155A5/ja
Application granted granted Critical
Publication of JP5836963B2 publication Critical patent/JP5836963B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012537925A 2009-11-03 2010-11-01 キナゾリン化合物 Expired - Fee Related JP5836963B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25764609P 2009-11-03 2009-11-03
US61/257,646 2009-11-03
PCT/US2010/054927 WO2011056740A1 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Publications (3)

Publication Number Publication Date
JP2013510155A JP2013510155A (ja) 2013-03-21
JP2013510155A5 true JP2013510155A5 (enExample) 2013-12-19
JP5836963B2 JP5836963B2 (ja) 2015-12-24

Family

ID=43970282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012537925A Expired - Fee Related JP5836963B2 (ja) 2009-11-03 2010-11-01 キナゾリン化合物

Country Status (13)

Country Link
US (1) US8859571B2 (enExample)
EP (1) EP2501233B1 (enExample)
JP (1) JP5836963B2 (enExample)
KR (1) KR101736521B1 (enExample)
CN (1) CN102711474B (enExample)
AU (1) AU2010315361B2 (enExample)
BR (1) BR112012010524A2 (enExample)
CA (1) CA2779989A1 (enExample)
EA (1) EA021439B1 (enExample)
ES (1) ES2523465T3 (enExample)
IL (1) IL219504A (enExample)
MX (1) MX2012005155A (enExample)
WO (1) WO2011056740A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398797B1 (en) * 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法
AU2014353006B2 (en) * 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
WO2015099916A1 (en) 2013-12-26 2015-07-02 Exxonmobil Research And Engineering Company Synthesis of zsm-48 crystals
KR20240017986A (ko) * 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
EP4031247A1 (en) 2019-09-16 2022-07-27 Novartis AG Bifunctional degraders and their methods of use
CA3233057A1 (en) 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases

Similar Documents

Publication Publication Date Title
RU2497813C2 (ru) 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2014511869A5 (enExample)
JP2013510876A5 (enExample)
JP2014525937A5 (enExample)
RU2016136997A (ru) 2-(гет)арил-замещенные конденсированные бициклические гетероциклические производные в качестве пестицидов
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
JP2017530999A5 (enExample)
JP2010513444A5 (enExample)
RU2018140092A (ru) Новые пиразолпиримидиновые производные
RU2012132692A (ru) Новые ингибиторы s-нитрозоглутатионредуктазы
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy
RU2012112151A (ru) Соединения как модуляторы тирозинкиназы
JP2021503458A5 (enExample)
HRP20170112T1 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
RU2016136116A (ru) Фармацевтические соединения
WO2012048181A4 (en) Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
CY1107433T1 (el) Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων
JP2009525978A5 (enExample)
JP2017522374A5 (enExample)
JP2017530185A5 (enExample)
WO2010143074A3 (en) Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
SI3075726T1 (en) DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS
CA2416874A1 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
JP2020510693A5 (enExample)